US EditionPublished • loading... • Updated
Protagonist Announces Icotrokinra Phase 2b ANTHEM-UC Trial Data to be Presented at the United European Gastroenterology Week Berlin 2025
Summary by Hastings Tribune
2 Articles
2 Articles
Hastings TribuneReposted by 
Weatherford Democrat
Weatherford DemocratProtagonist Announces Icotrokinra Phase 2b ANTHEM-UC Trial Data to be Presented at the United European Gastroenterology Week Berlin 2025
NEWARK, CALIFORNIA / ACCESS Newswire / September 15, 2025 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") announced that data from the Phase 2b ANTHEM-UC study with icotrokinra in ulcerative colitis will be the focus of a brief oral presentation…
Coverage Details
Total News Sources2
Leaning Left1Leaning Right0Center1Last UpdatedBias Distribution50% Left, 50% Center
Bias Distribution
- 50% of the sources lean Left, 50% of the sources are Center
50% Center
L 50%
C 50%
Factuality
To view factuality data please Upgrade to Premium
